GLPG Galapagos NV

95.21
-4.26  -4%
Previous Close 99.47
Open 96.56
Price To Book 3.85
Market Cap 5199874251
Shares 54,614,791
Volume 78,419
Short Ratio
Av. Daily Volume 78,041

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data lower than expectations released June 28, 2018.
GLPG2737 - PELICAN
Adult CF patients who are homozygous for the Class II F508del mutation
Phase 2 trial initiation announced July 5, 2017.
Filgotinib
Non-infectious uveitis
Phase 2 enrolment to be completed in 2019.
GLPG1972 - ROCCELLA
Osteoarthritis
Phase 2 data due 3Q 2019.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 initiated August 2016
Filgotinib - FINCH 4
Rheumatoid arthritis (RA)
Phase 3 data due 1Q 2019.
Filgotinib - FINCH 3
Rheumatoid arthritis (RA)
Phase 3 data released September 11, 2018. Endpoints met.
Filgotinib - FINCH 2
Rheumatoid arthritis (RA)
Phase 2 data released September 6, 2018. Primary endpoint met.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 2 data released May 30, 2018 - primary endpoint met.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 2a postive top-line data released November 20, 2017.
GLPG2222 - ALBATROSS
Cystic fibrosis (CF)
Phase 2 top-line data released December 20, 2016.
GLPG1837
Cystic Fibrosis
Phase 3 trial initiation announced December 17, 2018.
ISABELA - GLPG1690
Idiopathic pulmonary fibrosis
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 initiated November 2016. Enrollment to be completed 2H 2019.
Filgotinib - DIVERSITY
Crohn’s disease
Phase 3 data due 1Q 2019.
Filgotinib - FINCH 1
Rheumatoid arthritis (RA)
Phase 2 data due 2H 2019.
MOR106
Atopic dermatitis
Phase 2 enrolment to be completed in 2019.
GLPG1205 - PINTA
Idiopathic pulmonary fibrosis (IPF)
Phase 2 initiation announced January 7, 2019.
GLPG1690 - NOVESA
Systemic sclerosis

Latest News

  1. The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
  2. Galapagos increases share capital through warrant exercises
  3. 3 Top Biotech Stocks to Buy in March
  4. 2 Biotech Stocks With Major Incoming Catalysts
  5. Firmly on our way to becoming a fully integrated biopharma company
  6. The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut
  7. Evotec and Galapagos enter into collaboration in the field of fibrosis
  8. Sands Capital reports 5.7% holding in Galapagos
  9. Galapagos starts first Phase 1 trial with Toledo compound
  10. Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis
  11. Fibrocor and Galapagos sign partnership in fibrosis
  12. AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions
  13. How Should Investors React To Galapagos NV’s (AMS:GLPG) CEO Pay?
  14. Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference
  15. Recent Analysis Shows Best Buy Co., News Corporation, Semtech, Achaogen, Infosys, and Galapagos NV Market Influences — Renewed Outlook, Key Drivers of Growth
  16. Galapagos' Osteoarthritis Candidate Gets Fast Track Status
  17. Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis
  18. 5 Biotech Stocks to Scoop Up for Big Dividends
  19. Transparency notification